Sanofi to acquire Origimm Biotechnology to develop acne vaccine
Sanofi has entered into an agreement to acquire Origimm Biotechnology to add a potential first-in-class vaccine for acne to their pipeline.
List view / Grid view
Sanofi has entered into an agreement to acquire Origimm Biotechnology to add a potential first-in-class vaccine for acne to their pipeline.
The human medicines committee issue a positive opinion on the COVID-19 vaccine Comirnaty® in children aged five to under 12 years.
This whitepaper provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.
Telstar launches Usifroid global service platform for retrofitting & maintenance of freeze-dryers. To optimise and extend the life cycle of freeze-drying equipment from any brand or model.
This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Researchers have developed a novel platform technology, iVAX, that could enable the decentralised bioproduction of conjugate vaccines and enhance vaccination rates in developing nations.
18 November 2021 | By
The agreement enables the EU and European Economic Area (EEA) countries to donate Moderna's COVID-19 vaccine to low-income countries.
Download this whitepaper to discover the latest developments and research in QA/QC for biologic therapies via exclusive articles, interviews and application notes.
This application aims to replace the two separate compendial methods for the impurity analysis of gabapentin with one single HPLC method.
This webinar considers the fundamental importance of water system control within pharma processing and the best control and monitoring practices.
This whitepaper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods will not solve.
Kris Sterkens, Company Group Chairman of Janssen EMEA and Managing Director of Janssen Pharmaceutica considers how alterations made to COVID-19 vaccine development procedures could benefit future drug development pipelines.
Telstar promotes innovative aseptic production solutions in a setting marked by the new GMP Annex 1.
In this webinar, discover how an innovative 2-in-1 method for material analysis accelerates visual and chemical particle analysis in the pharmaceutical industry.
This flyer explains step-by-step how to perform your root cause analysis more efficiently, reliably and cost-effectively with a 2-in-1 solution for visual and chemical particle analysis.